BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

258 related articles for article (PubMed ID: 14647880)

  • 21. The effect of continuous oestradiol with intermittent norgestimate on bone mineral density and bone turnover in post-menopausal women.
    Arrenbrecht S; Caubel P; Garnero P; Felsenberg D
    Maturitas; 2004 Jul; 48(3):197-207. PubMed ID: 15207885
    [TBL] [Abstract][Full Text] [Related]  

  • 22. The prevention of osteoporosis using sequential low-dose hormone replacement therapy with estradiol-17 beta and dydrogesterone.
    Lees B; Stevenson JC
    Osteoporos Int; 2001; 12(4):251-8. PubMed ID: 11420773
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Effect of raloxifene on bone mineral density and biochemical markers of bone turnover in Japanese postmenopausal women with osteoporosis: results from a randomized placebo-controlled trial.
    Morii H; Ohashi Y; Taketani Y; Fukunaga M; Nakamura T; Itabashi A; Sarkar S; Harper K
    Osteoporos Int; 2003 Oct; 14(10):793-800. PubMed ID: 12955333
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Prevention of early postmenopausal bone loss by strontium ranelate: the randomized, two-year, double-masked, dose-ranging, placebo-controlled PREVOS trial.
    Reginster JY; Deroisy R; Dougados M; Jupsin I; Colette J; Roux C
    Osteoporos Int; 2002 Dec; 13(12):925-31. PubMed ID: 12459934
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Trimegestone in a low-dose, continuous-combined hormone therapy regimen prevents bone loss in osteopenic postmenopausal women.
    Warming L; Ravn P; Spielman D; Delmas P; Christiansen C
    Menopause; 2004; 11(3):337-42. PubMed ID: 15167314
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Prevention of osteoporosis and uterine effects in postmenopausal women taking raloxifene for 5 years.
    Jolly EE; Bjarnason NH; Neven P; Plouffe L; Johnston CC; Watts SD; Arnaud CD; Mason TM; Crans G; Akers R; Draper MW
    Menopause; 2003; 10(4):337-44. PubMed ID: 12851517
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Positive effect of alendronate on bone mineral density and markers of bone turnover in patients with rheumatoid arthritis on chronic treatment with low-dose prednisone: a randomized, double-blind, placebo-controlled trial.
    Lems WF; Lodder MC; Lips P; Bijlsma JW; Geusens P; Schrameijer N; van de Ven CM; Dijkmans BA
    Osteoporos Int; 2006; 17(5):716-23. PubMed ID: 16463007
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Safety and efficacy of drospirenone used in a continuous combination with 17beta-estradiol for prevention of postmenopausal osteoporosis.
    Warming L; Ravn P; Nielsen T; Christiansen C
    Climacteric; 2004 Mar; 7(1):103-11. PubMed ID: 15259289
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Three-year follow-up of the use of transdermal 17beta-estradiol matrix patches for the prevention of bone loss in early postmenopausal women.
    Delmas PD; Pornel B; Felsenberg D; Stakkestad JA; Radowicki S; Garnero P; Hardy P; Dain MP; Petitier B;
    Am J Obstet Gynecol; 2001 Jan; 184(2):32-40. PubMed ID: 11174476
    [TBL] [Abstract][Full Text] [Related]  

  • 30. A phase 3 trial of the efficacy and safety of oral recombinant calcitonin: the Oral Calcitonin in Postmenopausal Osteoporosis (ORACAL) trial.
    Binkley N; Bolognese M; Sidorowicz-Bialynicka A; Vally T; Trout R; Miller C; Buben CE; Gilligan JP; Krause DS;
    J Bone Miner Res; 2012 Aug; 27(8):1821-9. PubMed ID: 22437792
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Bisphosphonate risedronate prevents bone loss in women with artificial menopause due to chemotherapy of breast cancer: a double-blind, placebo-controlled study.
    Delmas PD; Balena R; Confravreux E; Hardouin C; Hardy P; Bremond A
    J Clin Oncol; 1997 Mar; 15(3):955-62. PubMed ID: 9060533
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Effects of bazedoxifene on BMD and bone turnover in postmenopausal women: 2-yr results of a randomized, double-blind, placebo-, and active-controlled study.
    Miller PD; Chines AA; Christiansen C; Hoeck HC; Kendler DL; Lewiecki EM; Woodson G; Levine AB; Constantine G; Delmas PD
    J Bone Miner Res; 2008 Apr; 23(4):525-35. PubMed ID: 18072873
    [TBL] [Abstract][Full Text] [Related]  

  • 33. The effect of 17beta-estradiol at doses of 0.5, 1 and 2 mg compared with placebo on early postmenopausal bone loss in hysterectomized women.
    Giske LE; Hall G; Rud T; Landgren BM
    Osteoporos Int; 2002; 13(4):309-16. PubMed ID: 12030546
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Cyclical etidronate therapy for prevention of postmenopausal bone loss: a 1-year open-label follow-up study.
    Fogelman I; Herd RJ; Blake GM; Balena R
    Calcif Tissue Int; 2000 May; 66(5):348-54. PubMed ID: 10773104
    [TBL] [Abstract][Full Text] [Related]  

  • 35. A combination of low doses of 17 beta-estradiol and norethisterone acetate prevents bone loss and normalizes bone turnover in postmenopausal women.
    Delmas PD; Confavreux E; Garnero P; Fardellone P; de Vernejoul MC; Cormier C; Arce JC
    Osteoporos Int; 2000; 11(2):177-87. PubMed ID: 10793878
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis.
    Li M; Zhang ZL; Liao EY; Chen DC; Liu J; Tao TZ; Wu W; Xia WB; Lu YJ; Sheng ZF; Lu CY; Meng GL; Xu L; Zhang WJ; Hu YY; Xu L
    Menopause; 2013 Jan; 20(1):72-8. PubMed ID: 22968256
    [TBL] [Abstract][Full Text] [Related]  

  • 37. The metabolic and bone density effects of continuous combined 17-beta estradiol and noresthisterone acetate treatments in Thai postmenopausal women: a double-blind placebo-controlled trial.
    Bunyavejchevin S; Limpaphayom KK
    J Med Assoc Thai; 2001 Jan; 84(1):45-53. PubMed ID: 11281499
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Prevention of postmenopausal bone loss by pulsed estrogen therapy: comparison with transdermal route.
    Delmas PD; Marianowski L; Perez Ade C; Ribot C; Pornel B; Palacios S; Lopes P;
    Maturitas; 2004 Jun; 48(2):85-96. PubMed ID: 15172082
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Estrogen-dependent increase in bone turnover and bone loss in postmenopausal women with breast cancer treated with anastrozole. Prevention with bisphosphonates.
    Confavreux CB; Fontana A; Guastalla JP; Munoz F; Brun J; Delmas PD
    Bone; 2007 Sep; 41(3):346-52. PubMed ID: 17618847
    [TBL] [Abstract][Full Text] [Related]  

  • 40. [Effects of estrogen therapy on bone mass in postmenopausal women with osteopenia].
    Insua A; Negri A; Zanchetta JR
    Medicina (B Aires); 1995; 55(5 Pt 1):408-14. PubMed ID: 8728770
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 13.